• $357.3M
    Market Cap
  • -38.49%
    1-Year Change
  • Biotechnology
    Industry

Key Performance

More
  • Earnings Score: N/A
  • Momentum Score: 28
  • True Yield: N/A
  • Financial Health Score: N/A
TradeSmith Loading

Latest Research & News

ProKidney Announces Eight Abstracts Selected for Presentation at the American Society of Nephrology’s Kidney Week 2026

ProKidney announced that eight abstracts, including one oral presentation, will be presented at ASN's Kidney Week 2026 in Denver. The abstracts present translational research and a pooled Phase 2 analysis supporting rilparencel's multifactorial mechanism of action for treating chronic kidney disease with type 2 diabetes, demonstrating kidney function stabilization and a strong safety profile.

10/02/2026, 9:00 AM • GlobeNewswire

ProKidney Reports Full Year 2025 Financial Results and Business Highlights

ProKidney reported full-year 2025 financial results with $270.0 million in cash and cash equivalents, supporting operations into mid-2027. The company achieved significant milestones including FDA alignment on an accelerated approval pathway for rilparencel using eGFR slope as a surrogate endpoint, positive Phase 2 REGEN-007 results, and strong enrollment momentum in the Phase 3 PROACT 1 study. The company expects to complete enrollment for the accelerated approval analysis by mid-2026 and deliver pivotal topline results in Q2 2027.

03/18/2026, 4:00 PM • GlobeNewswire

ProKidney Presents Full Results from the Phase 2 REGEN-007 Trial of Rilparencel at the American Society of Nephrology Kidney Week 2025

ProKidney presented Phase 2 trial results showing rilparencel potentially slows chronic kidney disease progression in diabetic patients, with statistically significant improvements in estimated glomerular filtration rate (eGFR) slope and no serious adverse events.

11/06/2025, 11:00 AM • GlobeNewswire

Peers

  • TNGX
    TANGO THERAPETCS
    $23.20-5.11%
    Market Cap$4.1B
    1-Year Change+217.95%
  • SEPN
    SEPTERNA
    $37.71-0.89%
    Market Cap$1.8B
    1-Year Change+88.83%
  • TYRA
    TYRA BIOSCIS
    $20.43-2.76%
    Market Cap$1.4B
    1-Year Change+56.91%
  • NBTX
    NANOBIOTIX SP ADS
    $25.75-7.71%
    Market Cap$1.4B
    1-Year Change+40.34%
  • BCAX
    BICARA THERAP
    $17.63-3.13%
    Market Cap$1.2B
    1-Year Change+8.92%
  • SVRA
    SAVARA
    $4.77-5.45%
    Market Cap$1.0B
    1-Year Change+44.56%
  • KURA
    Kura Oncology
    $10.74+0.85%
    Market Cap$947.4M
    1-Year Change+16.52%
  • PRME
    PRIME MEDICINE
    $3.00+0.33%
    Market Cap$542.3M
    1-Year Change-55.17%
  • RZLT
    REZOLUTE
    $4.01-1.47%
    Market Cap$391.9M
    1-Year Change-55.71%
  • EYPT
    EyePoint
    $3.25+0.62%
    Market Cap$278.5M
    1-Year Change-76.07%

Statistics

More
Day Range
$1.64
$1.76
$1.71
1-Year Range
$1.33
$3.30
$1.71
Latest Close$1.71
Change
+$0.05 (+2.92%)
Volume1,511,176
Market Cap$357.3M
Shares Outstanding208.9M
P/E (TTM)-3.07
Diluted EPS (TTM)-$0.56
Enterprise Value$282.4M

Information as of 10/01/2026

Company Profile

PROKIDNEY CORP
https://prokidney.com
$357.3M
Market Cap
-$84.2M
Net Income
Sector: Healthcare
Industry: Biotechnology
2000 Frontis Plaza Boulevard, Winston-Salem, NC, United States, 27103
336 999 7019

ProKidney Corp., a clinical-stage biotechnology company, engages in the development of cell therapies for the treatment of chronic kidney diseases in the United States. The company develops rilparencel, a cell therapy with autologous selected renal cells, which is in Phase III clinical trial for the treatment of advanced chronic kidney disease and type 2 diabetes. It is also involved in the development of cryopreserved versions of rilparencel, including REGEN-006 and REGEN-008 which are both in Phase III clinical trials; REGEN-002, REGEN-003, and REGEN-007 which are in Phase II clinical trials; and REGEN-004 which is Phase I clinical trial. The company was founded in 2015 and is headquartered in Winston-Salem, North Carolina.

Key Executives

  • Bruce Culleton
  • Todd C. Girolamo
  • James Coulston
  • Ulrich Ernst
  • Richard Williams

Current Ownership Distribution

  • Institutions358.7M (66.29%)
  • Insiders102.4M (18.92%)
  • Mutual Funds80.0M (14.78%)
  • Other0 (0.00%)